Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens Boots Alliance is contacting potential buyers considering a potential sale of its UK-based Boots drugstore chain in a second attempt at separating the unit, Bloomberg News reported on Monday, sending shares up 7%.

Walgreens seeks out potential buyers for sale of its UK Boots pharmacy chain, Bloomberg reports

Walgreens Boots Alliance Inc (NASDAQ:WBA, ETR:W8A)  shares are up 6.6% on a report that the US group is talking to potential buyers of its Boots arm. Advisers have been hired and potential buyers are being sounded out over the £7 billion UK chemist chain, according to a Bloomberg report.

Walgreens Boots seeks buyers for UK chemist chain as IPO plan evolves

Walgreens stock surged early Monday after Bloomberg reported the pharmacy chain is exploring selling its Boots chain.

Walgreens Stock Rallies On Report It's Booting UK Drugstores

Walgreens Boots Alliance Inc (NASDAQ: WBA) is gaining at writing following a report that it's contacting buyers who may be interested in taking over Boots. What is Boots UK worth?

Walgreens is reportedly contacting potential Boots buyers

Walmart is closing all of its health centers. As recently as last year, the company still had some bold plans for its growing healthcare business.

Walmart Is Closing Down Its Health Clinics. That's Not a Good Sign for Walgreens

JD.com

Warner Bros Discovery Inc

In a market that is sometimes obsessed with consumer names and high-flying tech companies, lesser-known stocks frequently go unnoticed. But among these many missed chances, three sleeper stocks have the potential to outperform the market and rise above their 52-week lows.

3 Sleeper Stocks Set to Surge Beyond 52-Week Lows

Clover Health Investments

CVS Health

For many investors, the concept of putting money into healthcare stocks to sell them at a future date might seem like a safe investment. After all, almost every person in the United States is dependent upon the corporatized healthcare system in some way or another.

3 Healthcare Stocks to Sell in May Before They Crash & Burn

Procter & Gamble

Unilever

If you're wondering which consumer staples stocks to sell this month, look no further. The consumer is hanging tough.

3 Consumer Staples Stocks to Sell in May Before They Crash & Burn

AT&T

May has historically been a month of market uncertainty on Wall Street, often characterized by the adage “Sell in May and go away.” While this strategy might not always hold true, it highlights the potential for increased volatility.

3 Stocks Perfectly Positioned to Weather Market Swings in May

Enterprise Products Partners

Kinder Morgan

MPLX

Williams

Earnings season presents buying opportunities for stocks that have experienced a dip in price after reporting Q1 earnings. Enterprise Products Partners offers a 7% yield and has strong fundamentals, including a well-covered distribution and positive outlook. CVS Health has a 5% yield and has been punished for higher medical utilization, but its pharmacy business is producing steadily growing results.

I'm Buying The Dip With Up To 7% Yield

American Express

Globe Life Inc

Hasbro

Micron Technology

Old Dominion Freight Line

Healthpeak Properties

Penn Entertainment

Progressive

Wells Fargo

For this month, the cycle/relative strength concept is applied. First, the S&P 500 stocks are ranked from the best performer to the worst by calculating the expected return in that month.

S&P Stocks To Trade In May

DEERFIELD, Ill. & RIDGEFIELD, Conn.--(BUSINESS WIRE)--Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable. This collaboration will offer people an opportunity to learn about and potentially participate in an important Phase III clinical trial within the familiar and accessible environment of Walgreens pharmacies, reflecting a shared vision to expand access to healthcare a.

ADDING MULTIMEDIA Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials

Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens (Nasdaq: WBA): UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION   VLADIMIR GUSINSKY REVOCABLE TRUST, Derivatively on Behalf of WALGREENS BOOTS ALLIANCE, INC.,   Plaintiff,   v.   STEFANO PESSINA, JOSE E. ALMEIDA, JANICE M. BABIAK, DAVID J. BRAILER, WILLIAM C. FOOTE, GINGER L. GRAHAM, JOHN A. LEDERER, DOMINIC MURPHY, LEONARD D. SCHAEFFER, NANCY M. SCHLICHTING, and JAMES A. SKINNER,   Defendants, and   WALGREENS BOOTS ALLIANCE.

Walgreens Boots Alliance Provides Summary Notice of Pending and Proposed Settlement of Shareholder Derivative Action

Amazon

Walmart

Walmart Inc. WMT, -0.43% announced Tuesday it's closing its 51 health centers after the retail giant admitted the business had not seen sustainable profits since its inception in 2019.

Walmart is closing down its health centers. What's that mean for Amazon, Walgreens and CVS?

Lululemon Athletica

Weightwatchers International Inc.

The U.S. economy is slowing, which is bad news for consumer stocks. In recent days, economic data showed that gross domestic product (GDP) in America grew at an annualized rate of 1.6% in the year's first quarter, considerably slower than the preceding quarter's 3.4% growth.

Stock Market Crash Warning: Don't Get Caught Holding These 3 Consumer Stocks.

Walgreens Boots Alliance (NYSE: WBA) stock price has become a toxic wasteland. It crashed to a low of $17 on Wednesday, much lower than its all-time high of $71.50, a 76% plunge.

Walgreens stock price forecast: is it too cheap or a value trap?

As Walgreens and Walmart scale back their investments in physician-staffed health clinics, they are forging ahead into the lucrative business of specialty pharmacy.

As Their Clinics Sputter, Walgreens And Walmart Invest More In Specialty Pharmacy

Nordstrom

Netflix

ServiceNow

Philip Morris

Spirit Airlines

Upstart Holdings

Just like how “buy” ratings from Wall Street analysts can give you great ideas to add to your watchlist, “sell” ratings from these analysts can also steer you away from the stocks to avoid. That said, much like how not every stock rated “buy” ends up being a profitable investment, not every stock rated “sell” ends up in the stock market graveyard.

Analysts Are Sounding the Alarm Bells on These 7 Stocks: April 2024

Citigroup

CoStar Group

Healthpeak Properties Inc

Hess

Newmont Mining

Royal Caribbean Cruises

Teradyne

Western Digital

Just about half of S&P 500 companies reported their first-quarter earnings. And they're coming in better than expected.

Corporate Profit Blasts Past Expectations Thanks To 10 Stocks

Walgreens, one of the largest retail pharmacy companies in the world, announced last week that it plans to launch a variety of new services as a part of its newly integrated specialty pharmacy business.

Walgreens' Next Frontier: Complex Conditions & Cell And Gene Therapy

Walgreens is launching Walgreens Specialty Pharmacy, a $24 billion business that integrates new gene and cell services with existing pharmacy assets including the large specialty pharmacy and home delivery business, AllianceRx.

Walgreens To Launch $24 Billion Business Dedicated To Specialty Pharmacy

Among the company's investments to "transform" its specialty pharmacy services is the opening of a new facility dedicated to cell and gene therapy services.

Walgreens to help bring cell and gene therapies to patients as it expands specialty pharmacy services

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is expanding its specialty pharmacy services and investing in its capabilities as the company further grows its core pharmacy business to improve patient outcomes and provide greater value to payers and partners. The company today introduced Walgreens Specialty Pharmacy, a holistic offering that expands access to care for patients with complex, chronic conditions and enables partnerships that drive profitability for Walgreens' pharmacy business. The c.

Walgreens Launches Gene and Cell Services as Part of Newly Integrated Walgreens Specialty Pharmacy Business

DoorDash

SAN FRANCISCO--(BUSINESS WIRE)--DoorDash (NASDAQ: DASH), the local commerce platform, and Walgreens (NASDAQ: WBA), a trusted, neighborhood health destination serving nearly 10 million customers each day, today announced a new collaboration to offer SNAP/EBT payment at nearly 7,800 Walgreens stores across the country. DoorDash is the first platform that enables SNAP customers to make purchases directly from Walgreens using their SNAP/EBT cards. In addition, DoorDash is the first third-party deli.

News for Walgreens Stock (WBA)